Agenovir Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

Agenovir General Information

Description

Developer of novel therapeutics designed to address diseases associated with or caused by, latent or persistent viral reservoirs. The company's novel therapeutics specialize in developing a novel class of nuclease-based anti-viral therapeutics to eliminate pathogenic viral genomes, enabling healthcare providers to treat their patients suffering from devastating and persistent viral infection.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 7000 Shoreline Court
  • Suite 320
  • South San Francisco, CA 94080
  • United States
Primary Industry
Biotechnology
Vertical(s)
Corporate Office
  • 7000 Shoreline Court
  • Suite 320
  • South San Francisco, CA 94080
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Agenovir Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 09-May-2018 Completed Generating Revenue
3. Early Stage VC (Series A) 17-May-2016 Completed Generating Revenue
2. Grant 01-Jan-2016 $149K Completed Generating Revenue
1. Accelerator/Incubator Completed Startup
To view Agenovir’s complete valuation and funding history, request access »

Agenovir Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
To view Agenovir’s complete cap table history, request access »

Agenovir Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel therapeutics designed to address diseases associated with or caused by, latent or persistent viral re
Biotechnology
South San Francisco, CA

Rochester, MN
 

Somerville, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Agenovir Competitors (46)

One of Agenovir’s 46 competitors is Vyriad, a Venture Capital-Backed company based in Rochester, MN.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Vyriad Venture Capital-Backed Rochester, MN
Genetix Biotherapeutics Private Equity-Backed Somerville, MA
Arisan Therapeutics Accelerator/Incubator Backed Carlsbad, CA
Aro Biotherapeutics Venture Capital-Backed Philadelphia, PA
CytoAgents Venture Capital-Backed Pittsburgh, PA
You’re viewing 5 of 46 competitors. Get the full list »

Agenovir Patents

Agenovir Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2020154594-A2 Compositions and methods for treatment of human papillomavirus Inactive 25-Jan-2019
WO-2020154594-A3 Compositions and methods for treatment of human papillomavirus Inactive 25-Jan-2019
EP-3601568-A1 Antiviral therapeutic Inactive 31-Mar-2017
WO-2018183808-A1 Antiviral therapeutic Inactive 31-Mar-2017
WO-2018183808-A9 Antiviral therapeutic Inactive 31-Mar-2017 C12N15/1131
To view Agenovir’s complete patent history, request access »

Agenovir Former Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Celgene Corporation Minority
DCVC Venture Capital Minority
Lightspeed Venture Partners Venture Capital Minority
QB3 Accelerator/Incubator
U.S. Department of Health and Human Services Government
To view Agenovir’s complete investors history, request access »

Agenovir FAQs

  • When was Agenovir founded?

    Agenovir was founded in 2014.

  • Where is Agenovir headquartered?

    Agenovir is headquartered in South San Francisco, CA.

  • What industry is Agenovir in?

    Agenovir’s primary industry is Biotechnology.

  • Is Agenovir a private or public company?

    Agenovir is a Private company.

  • What is Agenovir’s current revenue?

    The current revenue for Agenovir is .

  • How much funding has Agenovir raised over time?

    Agenovir has raised $10.6M.

  • Who are Agenovir’s investors?

    Celgene, DCVC, Lightspeed Venture Partners, QB3, and U.S. Department of Health and Human Services have invested in Agenovir.

  • Who are Agenovir’s competitors?

    Vyriad, Genetix Biotherapeutics, Arisan Therapeutics, Aro Biotherapeutics, and CytoAgents are some of the 46 competitors of Agenovir.

  • When was Agenovir acquired?

    Agenovir was acquired on 09-May-2018.

  • Who acquired Agenovir?

    Agenovir was acquired by Vir Biotechnology.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process